Release Date: December 11, 2025
Expiration Date: December 11, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in advanced prostate cancer. In this educational program, these experts use case-based examples to translate the latest evidence on PSMA PET and RLT—including combination strategies—into practical playbooks for selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.
This educational activity is an archive of the live symposium held on November 13, 2025.
Target Audience
This educational activity is directed toward physicians, pathologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners interested in prostate cancer.
Learning Objectives
At the conclusion of this activity, you should be better prepared
to:
- Evaluate the diagnostic and prognostic value of PSMA PET imaging and integrate imaging results into treatment planning for patients with advanced prostate cancer.
- Develop evidence-based sequencing strategies incorporating PSMA radioligands alongside AR pathway inhibitors, chemotherapy, and novel investigational agents.
- Identify real-world logistical, operational, and access-related barriers to PSMA-targeted imaging and therapy, and propose collaborative, multidisciplinary solutions to overcome them.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here